person · Reporting owner

BAUM CHARLES M

Disclosed activity across 7 companies

Tapewire entity: 36227
SEC CIK: 0001579824

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Acrivon Therapeutics, Inc.ACRV · Entity 573	Director	June 17, 2026	June 22, 2026
PMV Pharmaceuticals, Inc.PMVP · Entity 7062	Director	June 04, 2026	June 05, 2026
Tango Therapeutics, Inc.BCTG · Entity 1497	Director	September 02, 2020	September 03, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Acrivon Therapeutics, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-06-16	Direct	20,275	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 20,275 · Balance 20,275 F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

PMV Pharmaceuticals, Inc.

Report date June 04, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-06-04	Direct	42,000	Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 42,000 · Balance 42,000 F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Tango Therapeutics, Inc.

Report date September 02, 2020 · Filed September 03, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	40,600	Reported balance Holding disclosure · report date 2020-09-02 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 40,600

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARRAY BIOPHARMA INC

Report date July 30, 2019 · Filed July 30, 2019

Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-07-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-07-30 · Other · Disposed 15,000 · Balance 5,000 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.47 · Expires 2027-10-26	Direct	Reported balance After 2019-07-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on October 26, 2018.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.55 · Expires 2028-10-25	Direct	Reported balance After 2019-07-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6: The option provided for vesting in four equal annual installments beginning on October 25, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes.

F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.

F4: The option provided for vesting in four equal annual installments beginning on October 26, 2018.

F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F6: The option provided for vesting in four equal annual installments beginning on October 25, 2019.

IMMUNOMEDICS INC

Report date October 23, 2020 · Filed October 23, 2020

Section 16 reporting ended · disclosed 2020-10-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-10-23 transaction · row 1 1 source row Row 1 · 2020-10-23 · Disposition to issuer · Disposed 9,667 · Balance 0 F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-10-23 · Disposition to issuer · Disposed 46,117 · Balance 0 F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-23 · Disposition to issuer · Disposed 3,718 · Balance 0 F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.

F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

Mirati Therapeutics, Inc.

Report date January 23, 2024 · Filed January 23, 2024

Section 16 reporting ended · disclosed 2024-01-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2024-01-23 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2024-01-23 · Disposition to issuer · Disposed 123,389 · Balance 114,482 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. The number of shares of Company Common Stock (as defined below) reported in this Form 4 has been adjusted to account for a reconciliation of the Issuer's records in connection with the Merger. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 94,057 · Balance 20,425 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 20,425 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.40 · Expires 2027-01-25	Direct	Reported balance After 2024-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-23 · Disposition to issuer · Disposed 100,273 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.41 · Expires 2024-05-20	Direct	Reported balance After 2024-01-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-01-23 · Disposition to issuer · Disposed 69,258 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $21.51 · Expires 2025-02-03	Direct	Reported balance After 2024-01-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-01-23 · Disposition to issuer · Disposed 81,458 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $24.99 · Expires 2026-01-21	Direct	Reported balance After 2024-01-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-01-23 · Disposition to issuer · Disposed 111,652 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2028-01-17	Direct	Reported balance After 2024-01-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-01-23 · Disposition to issuer · Disposed 178,052 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20	Direct	Reported balance After 2024-01-23 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-01-23 · Disposition to issuer · Disposed 7,520 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $64.14 · Expires 2029-01-16	Direct	Reported balance After 2024-01-23 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-01-23 · Disposition to issuer · Disposed 1,559 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $64.14 · Expires 2029-01-16	Direct	Reported balance After 2024-01-23 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-01-23 · Disposition to issuer · Disposed 168,441 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. The number of shares of Company Common Stock (as defined below) reported in this Form 4 has been adjusted to account for a reconciliation of the Issuer's records in connection with the Merger.

F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.

F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.

F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.

F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option.

Poseida Therapeutics, Inc.

Report date January 08, 2025 · Filed January 08, 2025

Section 16 reporting ended · disclosed 2025-01-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-01-08 transaction · row 1 1 source row Row 1 · 2025-01-08 · Other · Disposed 78,600 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2032-06-15	Direct	Reported balance After 2025-01-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-01-08 · Disposition to issuer · Disposed 57,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5] F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2033-06-14	Direct	Reported balance After 2025-01-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-01-08 · Disposition to issuer · Disposed 27,350 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5] F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.81 · Expires 2034-06-16	Direct	Reported balance After 2025-01-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-01-08 · Disposition to issuer · Disposed 27,350 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5] F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]

F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 03, 2021 Filed Dec 3, 2021 20:09 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	985	$137.56	$135,495.22	Disclosure SEC source: 0001214659-21-012712 · marketforms-54505.xml · nonDerivative · entry 8 BAUM CHARLES M · CIK 0001579824 · Director · President & Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,714 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $137.34 to $137.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 03, 2021 Filed Dec 3, 2021 20:09 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	1,210	$136.66	$165,360.90	Disclosure SEC source: 0001214659-21-012712 · marketforms-54505.xml · nonDerivative · entry 7 BAUM CHARLES M · CIK 0001579824 · Director · President & Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,699 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $136.29 to $137.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 03, 2021 Filed Dec 3, 2021 20:09 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	6,558	$135.64	$889,538.92	Disclosure SEC source: 0001214659-21-012712 · marketforms-54505.xml · nonDerivative · entry 6 BAUM CHARLES M · CIK 0001579824 · Director · President & Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,909 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $135.15 to $136.135. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 03, 2021 Filed Dec 3, 2021 20:09 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	3,842	$134.57	$517,023.32	Disclosure SEC source: 0001214659-21-012712 · marketforms-54505.xml · nonDerivative · entry 5 BAUM CHARLES M · CIK 0001579824 · Director · President & Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $134.15 to $135.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 03, 2021 Filed Dec 3, 2021 20:09 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	3,900	$133.27	$519,744.42	Disclosure SEC source: 0001214659-21-012712 · marketforms-54505.xml · nonDerivative · entry 4 BAUM CHARLES M · CIK 0001579824 · Director · President & Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,309 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $133.07 to $134.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 03, 2021 Filed Dec 3, 2021 20:09 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	21,509	$132.49	$2,849,720.96	Disclosure SEC source: 0001214659-21-012712 · marketforms-54505.xml · nonDerivative · entry 3 BAUM CHARLES M · CIK 0001579824 · Director · President & Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,209 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $132.07 to $133.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 03, 2021 Filed Dec 3, 2021 20:09 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	9,200	$131.61	$1,210,803.72	Disclosure SEC source: 0001214659-21-012712 · marketforms-54505.xml · nonDerivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,718 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $131.07 to $132.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 03, 2021 Filed Dec 3, 2021 20:09 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	47,204	$8.49	$400,761.96	Disclosure SEC source: 0001214659-21-012712 · marketforms-54505.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. Read SEC document
June 18, 2021 Filed Jun 21, 2021 17:12 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $8.49	$0.00	Disclosure SEC source: 0001214659-21-006762 · marketforms-53168.xml · derivative · entry 6 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,204 Underlying: Common Stock · 40,000 shares Expires 2022-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. Read SEC document
June 18, 2021 Filed Jun 21, 2021 17:12 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	1,023	$166.73	$170,565.81	Disclosure SEC source: 0001214659-21-006762 · marketforms-53168.xml · nonDerivative · entry 5 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,714 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $166.53 to $166.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 18, 2021 Filed Jun 21, 2021 17:12 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	20,823	$166.07	$3,457,986.07	Disclosure SEC source: 0001214659-21-006762 · marketforms-53168.xml · nonDerivative · entry 4 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,737 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $165.53 to $166.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 18, 2021 Filed Jun 21, 2021 17:12 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	13,338	$164.90	$2,199,498.89	Disclosure SEC source: 0001214659-21-006762 · marketforms-53168.xml · nonDerivative · entry 3 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,560 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $164.47 to $165.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 18, 2021 Filed Jun 21, 2021 17:12 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	4,816	$164.07	$790,181.83	Disclosure SEC source: 0001214659-21-006762 · marketforms-53168.xml · nonDerivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,898 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $163.45 to $164.41. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 18, 2021 Filed Jun 21, 2021 17:12 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	40,000	$8.49	$339,600.00	Disclosure SEC source: 0001214659-21-006762 · marketforms-53168.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. Read SEC document
June 02, 2021 Filed Jun 9, 2021 21:28 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	GrantStock Option (right to buy) · Derivative	16,333	$0.00 Strike: $32.29	$0.00	Disclosure SEC source: 0001209191-21-039235 · doc4.xml · derivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,333 Underlying: Common Stock · 16,333 shares Expires 2031-06-01 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 2, 2022 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document
April 05, 2021 Filed Apr 7, 2021 20:28 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	GrantStock Option (right to buy) · Derivative	32,677	$0.00 Strike: $34.11	$0.00	Disclosure SEC source: 0001209191-21-025880 · doc4.xml · derivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,677 Underlying: Common Stock · 32,677 shares Expires 2031-04-05 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on May 5, 2021. Read SEC document
January 26, 2021 Filed Jan 28, 2021 17:45 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,292	$0.00 Strike: $5.40	$0.00	Disclosure SEC source: 0001214659-21-000938 · marketforms-51292.xml · derivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,273 Underlying: Common Stock · 2,292 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document
January 26, 2021 Filed Jan 28, 2021 17:45 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	2,292	$5.40	$12,376.80	Disclosure SEC source: 0001214659-21-000938 · marketforms-51292.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 19, 2021 Filed Jan 20, 2021 18:17 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	3,245	$0.00 Strike: $27.00	$0.00	Disclosure SEC source: 0001214659-21-000682 · marketforms-50972.xml · derivative · entry 4 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,755 Underlying: common Stock · 3,245 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document
January 19, 2021 Filed Jan 20, 2021 18:17 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	3,245	$27.00	$87,615.00	Disclosure SEC source: 0001214659-21-000682 · marketforms-50972.xml · nonDerivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 15, 2021 Filed Jan 20, 2021 18:17 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantEmployee Stock Option (Right to Buy) · Derivative	30,742	$0.00 Strike: $214.47	$0.00	Disclosure SEC source: 0001214659-21-000682 · marketforms-50972.xml · derivative · entry 3 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,742 Underlying: Common Stock · 30,742 shares Expires 2031-01-14 F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document
January 15, 2021 Filed Jan 20, 2021 18:17 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	19,665	$0.00	$0.00	Disclosure SEC source: 0001214659-21-000682 · marketforms-50972.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,177 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document
January 06, 2021 Filed Jan 8, 2021 19:14 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	4,421	$210.28	$929,647.88	Disclosure SEC source: 0001214659-21-000332 · marketforms-50904.xml · nonDerivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,512 F1 · kind: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 3, 2020. Read SEC document
January 06, 2021 Filed Jan 8, 2021 19:14 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	90	$215.76	$19,418.34	Disclosure SEC source: 0001214659-21-000332 · marketforms-50904.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,933 F1 · kind: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 3, 2020. Read SEC document
December 29, 2020 Filed Dec 31, 2020 18:39 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GiftCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001214659-20-010883 · marketforms-50778.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,023 Read SEC document
December 18, 2020 Filed Dec 21, 2020 18:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $8.49	$0.00	Disclosure SEC source: 0001214659-20-010598 · marketforms-50689.xml · derivative · entry 9 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,204 Underlying: Common Stock · 40,000 shares Expires 2022-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2020 Filed Dec 21, 2020 18:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	317	$240.23	$76,152.91	Disclosure SEC source: 0001214659-20-010598 · marketforms-50689.xml · nonDerivative · entry 8 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,023 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. Read SEC document
December 18, 2020 Filed Dec 21, 2020 18:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	100	$238.76	$23,875.50	Disclosure SEC source: 0001214659-20-010598 · marketforms-50689.xml · nonDerivative · entry 7 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,340 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. Read SEC document
December 18, 2020 Filed Dec 21, 2020 18:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	2,020	$237.26	$479,255.10	Disclosure SEC source: 0001214659-20-010598 · marketforms-50689.xml · nonDerivative · entry 6 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,440 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $237.10 to $238.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 18, 2020 Filed Dec 21, 2020 18:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	4,250	$236.17	$1,003,731.85	Disclosure SEC source: 0001214659-20-010598 · marketforms-50689.xml · nonDerivative · entry 5 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,460 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $235.80 to $236.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 18, 2020 Filed Dec 21, 2020 18:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	493	$235.20	$115,955.67	Disclosure SEC source: 0001214659-20-010598 · marketforms-50689.xml · nonDerivative · entry 4 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,710 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $234.745 to $235.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 18, 2020 Filed Dec 21, 2020 18:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	22,932	$234.26	$5,371,997.58	Disclosure SEC source: 0001214659-20-010598 · marketforms-50689.xml · nonDerivative · entry 3 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,203 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $233.71 to $234.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 18, 2020 Filed Dec 21, 2020 18:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	9,888	$233.43	$2,308,144.96	Disclosure SEC source: 0001214659-20-010598 · marketforms-50689.xml · nonDerivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,135 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $232.68 to $233.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 18, 2020 Filed Dec 21, 2020 18:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	40,000	$8.49	$339,600.00	Disclosure SEC source: 0001214659-20-010598 · marketforms-50689.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. Read SEC document
October 23, 2020 Filed Oct 23, 2020 17:32 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Disposition to issuerRestricted Stock Unit · Derivative	3,718	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-117793 · a4.xml · derivative · entry 3 BAUM CHARLES M · CIK 0001579824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,718 shares Expires not disclosed F3 · derivative.exercise_price: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. F3 · price: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. F3 · derivative.exercise_date: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. F3 · derivative.expiration_date: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. Read SEC document
October 23, 2020 Filed Oct 23, 2020 17:32 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Disposition to issuerStock Option (Right to Buy) · Derivative	46,117	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-117793 · a4.xml · derivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,117 shares Expires not disclosed F2 · derivative.exercise_price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · derivative.expiration_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. Read SEC document
October 23, 2020 Filed Oct 23, 2020 17:32 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Disposition to issuerCommon Stock	9,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-117793 · a4.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. F1 · price: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. Read SEC document
July 23, 2020 Filed Jul 24, 2020 17:30 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GiftCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001214659-20-006523 · marketforms-49357.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,023 Read SEC document
June 18, 2020 Filed Jun 22, 2020 17:20 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Option (right to buy) · Derivative	6,540	$0.00 Strike: $33.62	$0.00	Disclosure SEC source: 0001104659-20-075697 · a4.xml · derivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,540 Underlying: Common Stock, par value $0.01 per share · 6,540 shares Expires 2030-06-18 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020. F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document
June 18, 2020 Filed Jun 22, 2020 17:20 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantCommon Stock, $0.01 par value per share	3,718	$0.00	$0.00	Disclosure SEC source: 0001104659-20-075697 · a4.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,385 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020. F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document
April 27, 2020 Filed Apr 28, 2020 20:49 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	557	$0.00 Strike: $5.40	$0.00	Disclosure SEC source: 0001214659-20-003834 · marketforms-48644.xml · derivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,565 Underlying: Common Stock · 557 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document
April 27, 2020 Filed Apr 28, 2020 20:49 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	557	$5.40	$3,007.80	Disclosure SEC source: 0001214659-20-003834 · marketforms-48644.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 17, 2020 Filed Apr 20, 2020 16:59 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $8.49	$0.00	Disclosure SEC source: 0001214659-20-003519 · marketforms-48589.xml · derivative · entry 5 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,204 Underlying: Common Stock · 40,000 shares Expires 2022-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 17, 2020 Filed Apr 20, 2020 16:59 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	4,290	$91.63	$393,092.27	Disclosure SEC source: 0001214659-20-003519 · marketforms-48589.xml · nonDerivative · entry 4 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,466 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $91.10 to $91.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
April 17, 2020 Filed Apr 20, 2020 16:59 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	25,184	$90.41	$2,276,958.47	Disclosure SEC source: 0001214659-20-003519 · marketforms-48589.xml · nonDerivative · entry 3 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,756 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $90.08 to $90.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
April 17, 2020 Filed Apr 20, 2020 16:59 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	10,526	$89.59	$943,058.02	Disclosure SEC source: 0001214659-20-003519 · marketforms-48589.xml · nonDerivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,940 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $89.08 to $90.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
April 17, 2020 Filed Apr 20, 2020 16:59 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	40,000	$8.49	$339,600.00	Disclosure SEC source: 0001214659-20-003519 · marketforms-48589.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. Read SEC document
March 27, 2020 Filed Mar 30, 2020 17:52 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,291	$0.00 Strike: $5.40	$0.00	Disclosure SEC source: 0001214659-20-003016 · marketforms-48461.xml · derivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,122 Underlying: Common Stock · 2,291 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document
March 27, 2020 Filed Mar 30, 2020 17:52 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	2,291	$5.40	$12,371.40	Disclosure SEC source: 0001214659-20-003016 · marketforms-48461.xml · nonDerivative · entry 1 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 28, 2020 Filed Mar 2, 2020 16:28 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,291	$0.00 Strike: $5.40	$0.00	Disclosure SEC source: 0001214659-20-002048 · marketforms-48019.xml · derivative · entry 2 BAUM CHARLES M · CIK 0001579824 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,413 Underlying: Common Stock · 2,291 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.